Stay updated on Sparsentan in IgA Nephropathy: Clinical Trial
Sign up to get notified when there's something new on the Sparsentan in IgA Nephropathy: Clinical Trial page.

Latest updates to the Sparsentan in IgA Nephropathy: Clinical Trial page
- Check6 days agoChange DetectedAdded a new publication citation under Publications: 'Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy' (Clin J Am Soc Nephrol, 2025).SummaryDifference0.0%

- Check13 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no visible changes to core content or layout were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check20 days agoChange DetectedRevision: v3.4.1 replaces the previous v3.4.0, which appears to be a minor version update with no impact on study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedAdded a glossary toggle and updated metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0). Removed older wording (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).SummaryDifference0.1%

- Check42 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4; no visible changes to core study content are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded new trial locations across the United States, Australia, and Europe and removed several existing locations, altering the geographic availability of study sites. This affects where participants can enroll and access the trial.SummaryDifference3%

Stay in the know with updates to Sparsentan in IgA Nephropathy: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sparsentan in IgA Nephropathy: Clinical Trial page.